Giorgos Bamias

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5025407/publications.pdf

Version: 2024-02-01

87888 102487 4,809 108 38 66 citations g-index h-index papers 110 110 110 6122 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Probiotics promote gut health through stimulation of epithelial innate immunity. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 454-459.	7.1	298
2	Expression, Localization, and Functional Activity of TL1A, a Novel Th1-Polarizing Cytokine in Inflammatory Bowel Disease. Journal of Immunology, 2003, 171, 4868-4874.	0.8	272
3	TNF-αneutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8366-8371.	7.1	182
4	New Concepts in the Pathophysiology of Inflammatory Bowel Disease. Annals of Internal Medicine, 2005, 143, 895.	3.9	175
5	SAMP1/YitFc mouse strain: A spontaneous model of Crohn $\hat{E}^{1}\!\!/_{4}$ s disease-like ileitis. Inflammatory Bowel Diseases, 2011, 17, 2566-2584.	1.9	159
6	Role of TL1A and its receptor DR3 in two models of chronic murine ileitis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 8441-8446.	7.1	157
7	Emergence of perianal fistulizing disease in the SAMP1/YitFc mouse, a spontaneous model of chronic ileitis. Gastroenterology, 2003, 124, 972-982.	1.3	156
8	Proinflammatory effects of TH2 cytokines in a murine model of chronic small intestinal inflammation. Gastroenterology, 2005, 128, 654-666.	1.3	150
9	Results of the 4th scientific workshop of the ECCO (I): Pathophysiology of intestinal fibrosis in IBD. Journal of Crohn's and Colitis, 2014, 8, 1147-1165.	1.3	131
10	L-Selectin, $\hat{l}\pm4\hat{l}^21$, and $\hat{l}\pm4\hat{l}^27$ Integrins Participate in CD4+ T Cell Recruitment to Chronically Inflamed Small Intestine. Journal of Immunology, 2005, 174, 2343-2352.	0.8	130
11	Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 429-436.	1.3	106
12	Cellular and Molecular Mediators of Intestinal Fibrosis. Journal of Crohn's and Colitis, 2017, 11, j.crohns.2014.09.008.	1.3	99
13	Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis. Clinical Immunology, 2008, 129, 249-255.	3.2	97
14	Histological spectrum of mycophenolate mofetilâ€related colitis: association with apoptosis. Histopathology, 2013, 63, 649-658.	2.9	94
15	Results of the Fifth Scientific Workshop of the ECCO (II): Pathophysiology of Perianal Fistulizing Disease. Journal of Crohn's and Colitis, 2016, 10, 377-386.	1.3	92
16	Immunopathogenesis of inflammatory bowel disease: current concepts. Current Opinion in Gastroenterology, 2007, 23, 365-369.	2.3	91
17	New insights into the dichotomous role of innate cytokines in gut homeostasis and inflammation. Cytokine, 2012, 59, 451-459.	3.2	90
18	GSDMB is increased in IBD and regulates epithelial restitution/repair independent of pyroptosis. Cell, 2022, 185, 283-298.e17.	28.9	86

#	Article	IF	CITATIONS
19	Down-Regulation of Intestinal Lymphocyte Activation and Th1 Cytokine Production by Antibiotic Therapy in a Murine Model of Crohn's Disease. Journal of Immunology, 2002, 169, 5308-5314.	0.8	84
20	Experimental colitis models: Insights into the pathogenesis of inflammatory bowel disease and translational issues. European Journal of Pharmacology, 2015, 759, 253-264.	3.5	84
21	Changing Pattern in the Clinical Presentation of Pediatric Celiac Disease: A 30-Year Study. Digestion, 2009, 80, 185-191.	2.3	76
22	Commensal Bacteria Exacerbate Intestinal Inflammation but Are Not Essential for the Development of Murine lleitis. Journal of Immunology, 2007, 178, 1809-1818.	0.8	74
23	Balkan Nephropathy: Evolution of Our Knowledge. American Journal of Kidney Diseases, 2008, 52, 606-616.	1.9	74
24	Role of the IL-23/IL-17 axis in Crohn's disease. Discovery Medicine, 2012, 14, 253-62.	0.5	71
25	High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis. Clinical Immunology, 2010, 137, 242-249.	3.2	68
26	Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy. Cancer Investigation, 2017, 35, 443-455.	1.3	67
27	Upregulation and nuclear localization of TNFâ€like Cytokine 1A (TL1A) and its receptors DR3 and DcR3 in psoriatic skin lesions. Experimental Dermatology, 2011, 20, 725-731.	2.9	64
28	IL-33 Drives Eosinophil Infiltration and Pathogenic Type 2 Helper T-Cell Immune Responses Leading to Chronic Experimental Ileitis. American Journal of Pathology, 2016, 186, 885-898.	3.8	62
29	Expanded B cell population blocks regulatory T cells and exacerbates ileitis in a murine model of Crohn disease. Journal of Clinical Investigation, 2004, 114, 389-398.	8.2	59
30	Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World Journal of Gastroenterology, 2017, 23, 7387-7396.	3.3	59
31	TL1A (TNFSF15) and DR3 (TNFRSF25): A Co-stimulatory System of Cytokines With Diverse Functions in Gut Mucosal Immunity. Frontiers in Immunology, 2019, 10, 583.	4.8	57
32	Role of type 2 immunity in intestinal inflammation. Current Opinion in Gastroenterology, 2015, 31, 471-476.	2.3	49
33	Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts. Inflammatory Bowel Diseases, 2019, 25, 270-282.	1.9	48
34	The TL1A/DR3/DcR3 pathway in autoimmune rheumatic diseases. Seminars in Arthritis and Rheumatism, 2015, 45, 1-8.	3.4	46
35	Markers of bacterial translocation in end-stage liver disease. World Journal of Hepatology, 2015, 7, 2264.	2.0	45
36	Systematic review with metaâ€analysis: COVIDâ€19 outcomes in patients receiving antiâ€TNF treatments. Alimentary Pharmacology and Therapeutics, 2022, 55, 154-167.	3.7	42

3

#	Article	IF	CITATIONS
37	Differential expression of the TL1A/DcR3 system of TNF/TNFR-like proteins in large vs. small intestinal Crohn's disease. Digestive and Liver Disease, 2012, 44, 30-36.	0.9	41
38	Tumor Necrosis Factor–like Cytokine TL1A and Its Receptors DR3 and DcR3. Inflammatory Bowel Diseases, 2015, 21, 1.	1.9	41
39	A Novel Role for TL1A/DR3 in Protection against Intestinal Injury and Infection. Journal of Immunology, 2016, 197, 377-386.	0.8	41
40	Neutralization of IL-1α ameliorates Crohn's disease-like ileitis by functional alterations of the gut microbiome. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26717-26726.	7.1	41
41	Cytokines and mucosal immunity. Current Opinion in Gastroenterology, 2014, 30, 547-552.	2.3	40
42	Leukocyte Traffic Blockade as a Therapeutic Strategy in Inflammatory Bowel Disease. Current Drug Targets, 2013, 14, 1490-1500.	2.1	38
43	Cytokines in the pathogenesis of ulcerative colitis. Discovery Medicine, 2011, 11, 459-67.	0.5	38
44	Risk factors for bloodstream infection with Klebsiella pneumoniae producing VIM-1 metallo-Â-lactamase. Journal of Antimicrobial Chemotherapy, 2010, 65, 784-788.	3.0	36
45	Cytokines and intestinal inflammation. Current Opinion in Gastroenterology, 2016, 32, 437-442.	2.3	34
46	Resistin-Like Molecule \hat{I}^2 (RELM \hat{I}^2 /FIZZ2) Is Highly Expressed in the Ileum of SAMP1/YitFc Mice and Is Associated with Initiation of Ileitis. Journal of Immunology, 2007, 179, 7012-7020.	0.8	33
47	Increased levels of soluble TNF-like cytokine 1A in ankylosing spondylitis. Rheumatology, 2013, 52, 448-451.	1.9	33
48	Intestinal-Specific TNFα Overexpression Induces Crohn's-Like Ileitis in Mice. PLoS ONE, 2013, 8, e72594.	2.5	32
49	Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis. World Journal of Gastrointestinal Pathophysiology, 2014, 5, 293.	1.0	32
50	Mouse models of inflammatory bowel disease for investigating mucosal immunity in the intestine. Current Opinion in Gastroenterology, 2017, 33, 411-416.	2.3	31
51	Comparative Study of Candidate Housekeeping Genes for Quantification of Target Gene Messenger RNA Expression by Real-Time PCR in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 2840-2847.	1.9	30
52	Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. Journal of Clinical Medicine, 2020, 9, 3533.	2.4	29
53	Checkpoint inhibitor colitis. Current Opinion in Gastroenterology, 2018, 34, 377-383.	2.3	28
54	Pathway-based approaches to the treatment of inflammatory bowel disease. Translational Research, 2016, 167, 104-115.	5.0	26

#	Article	IF	CITATIONS
55	Reliability and applicability of two-dimensional shear-wave elastography for the evaluation of liver stiffness. European Journal of Gastroenterology and Hepatology, 2016, 28, 1204-1209.	1.6	25
56	Crohn's disease-associated mucosal factors regulate the expression of TNF-like cytokine 1A and its receptors in primary subepithelial intestinal myofibroblasts and intestinal epithelial cells. Translational Research, 2017, 180, 118-130.e2.	5.0	23
57	Cytokine Receptor Profiling in Human Colonic Subepithelial Myofibroblasts: A Differential Effect of Th Polarization–Associated Cytokines in Intestinal Fibrosis. Inflammatory Bowel Diseases, 2018, 24, 2224-2241.	1.9	23
58	Mucins in neoplasms of pancreas, ampulla of Vater and biliary system. World Journal of Gastrointestinal Oncology, 2016, 8, 725.	2.0	23
59	The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era. Rheumatology International, 2022, 42, 1493-1511.	3.0	22
60	Novel strategies to attenuate immune activation in Crohn's disease. Current Opinion in Pharmacology, 2006, 6, 401-407.	3.5	21
61	Immunological Regulation of Intestinal Fibrosis in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2022, 28, 337-349.	1.9	20
62	Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors. Cancer Immunology Research, 2021, 9, 726-734.	3.4	19
63	The tumor necrosis factor-like cytokine 1A/death receptor 3 cytokine system in intestinal inflammation. Current Opinion in Gastroenterology, 2013, 29, 597-602.	2.3	18
64	Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn's Disease Patients. Gastroenterology Research and Practice, 2018, 2018, 1-9.	1.5	16
65	Type I and II Interferon Signatures Can Predict the Response to Anti-TNF Agents in Inflammatory Bowel Disease Patients: Involvement of the Microbiota. Inflammatory Bowel Diseases, 2020, 26, 1543-1553.	1.9	16
66	The Greek Response to COVID-19: A True Success Story from an IBD Perspective. Inflammatory Bowel Diseases, 2020, 26, 1144-1148.	1.9	16
67	The IBD-F Patient Self-Assessment Scale Accurately Depicts the Level of Fatigue and Predicts a Negative Effect on the Quality of Life of Patients With IBD in Clinical Remission. Inflammatory Bowel Diseases, 2021, 27, 826-835.	1.9	16
68	Lung fibrosis-associated soluble mediators and bronchoalveolar lavage from idiopathic pulmonary fibrosis patients promote the expression of fibrogenic factors in subepithelial lung myofibroblasts. Pulmonary Pharmacology and Therapeutics, 2017, 46, 78-87.	2.6	15
69	Antibody secreting cells are critically dependent on integrin $\hat{l}\pm4\hat{l}^27/MAdCAM-1$ for intestinal recruitment and control of the microbiota during chronic colitis. Mucosal Immunology, 2022, 15, 109-119.	6.0	15
70	Structures, Locations, and Transfer Frequencies of Genetic Elements Conferring High-Level Gentamicin Resistance in Enterococcus faecalis Isolates in Greece. Antimicrobial Agents and Chemotherapy, 2003, 47, 3950-3953.	3.2	13
71	Development of a Human Intestinal Organoid Model for In Vitro Studies on Gut Inflammation and Fibrosis. Stem Cells International, 2021, 2021, 1-14.	2.5	13
72	Candida tropicalis Infection Modulates the Gut Microbiome and Confers Enhanced Susceptibility to Colitis in Mice. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 901-923.	4.5	11

#	Article	IF	CITATIONS
73	Atypical Mycobacterial Infection Presenting as Persistent Skin Lesion in a Patient with Ulcerative Colitis. Case Reports in Medicine, 2011, 2011, 1-4.	0.7	10
74	Strongyloides hyperinfection syndrome presenting as enterococcal meningitis in a low-endemicity area. Virulence, 2010, 1, 468-470.	4.4	9
75	Serum Vitamins D, B9 and B12 in Greek Patients with Inflammatory Bowel Diseases. Nutrients, 2020, 12, 3734.	4.1	9
76	An integrin $\hat{l}\pm\hat{l}^2$ 7-dependent mechanism of IgA transcytosis requires direct plasma cell contact with intestinal epithelium. Mucosal Immunology, 2021, 14, 1347-1357.	6.0	9
77	Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF. Digestive and Liver Disease, 2017, 49, 29-33.	0.9	8
78	Early ileocolonoscopy with biopsy for the evaluation of persistent post-transplantation diarrhea. World Journal of Gastroenterology, 2010, 16, 3834.	3.3	8
79	Exploring the Early Phase of Crohn's Disease. Clinical Gastroenterology and Hepatology, 2020, 19, 2469-2480.	4.4	7
80	Inherent Immune Cell Variation Within Colonic Segments Presents Challenges for Clinical Trial Design. Journal of Crohn's and Colitis, 2020, 14, 1364-1377.	1.3	7
81	Effects of Anti-Inflammatory Treatment and Surgical Intervention on Endothelial Glycocalyx, Peripheral and Coronary Microcirculatory Function and Myocardial Deformation in Inflammatory Bowel Disease Patients: A Two-Arms Two-Stage Clinical Trial. Diagnostics, 2021, 11, 993.	2.6	7
82	The natural history of COVID-19 in patients with inflammatory bowel disease: a nationwide study by the Hellenic Society for the study of IBD. European Journal of Gastroenterology and Hepatology, 2021, 33, e810-e817.	1.6	7
83	TL1A as a therapeutic target in inflammatory bowel disease. Expert Review of Clinical Immunology, 2022, 18, 551-555.	3.0	7
84	Innate Cytokines Dictate the Fate of Acute Intestinal Inflammation. Gastroenterology, 2015, 148, 248-250.	1.3	6
85	Elevated Serum Levels of the Antiapoptotic Protein Decoy-Receptor 3 Are Associated with Advanced Liver Disease. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-8.	1.9	6
86	Response to Anti- $\hat{l}\pm4\hat{l}^27$ Blockade in Patients With Ulcerative Colitis Is Associated With Distinct Mucosal Gene Expression Profiles at Baseline. Inflammatory Bowel Diseases, 2022, 28, 87-95.	1.9	6
87	Real-World Use and Adverse Events of SARS-CoV-2 Vaccination in Greek Patients with Inflammatory Bowel Disease. Journal of Clinical Medicine, 2022, 11, 641.	2.4	6
88	Ability to Reverse Deeper Levels of Unintended Sedation. Digestion, 2010, 82, 94-96.	2.3	5
89	Synchronous cytomegalovirus and Clostridium difficile infection of the pouch: a trigger for chronic pouchitis?. Clinical Journal of Gastroenterology, 2014, 7, 132-135.	0.8	5
90	Death-Domain-Receptor 3 Deletion Normalizes Inflammatory Gene Expression and Prevents Ileitis in Experimental Crohn's Disease. Inflammatory Bowel Diseases, 2019, 25, 14-26.	1.9	5

#	Article	IF	Citations
91	Endothelial and Cardiac Dysfunction in Inflammatory Bowel Diseases: Does Treatment Modify the Inflammatory Load on Arterial and Cardiac Structure and Function?. Current Vascular Pharmacology, 2019, 18, 27-37.	1.7	5
92	Clinical profiles of moderate and severe Crohn's disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines. Annals of Gastroenterology, 2015, 28, 417-25.	0.6	5
93	Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort. Digestive Diseases and Sciences, 2022, 67, 1007-1017.	2.3	4
94	Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment. World Journal of Gastroenterology, 2021, 27, 3762-3779.	3.3	4
95	Possible infection diagnosed by videocapsule endoscopy in an immunocompetent patient with devastating diarrhea. Annals of Gastroenterology, 2012, 25, 268-270.	0.6	4
96	Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry. Inflammatory Bowel Diseases, 2023, 29, 228-237.	1.9	4
97	Efficacy of IL12/23 Blockade Expands Our Therapeutic Targets and Challenges the Old Dogma in Ulcerative Colitis. Gastroenterology, 2020, 158, 1836-1837.	1.3	3
98	Enteric plexus neuropathy associated with PD-L1 blockade in a patient with small-cellÂlung cancer. Immunotherapy, 2021, 13, 1085-1092.	2.0	3
99	Inflammatory infiltration of metaplastic epithelium and correlation to previous diagnosis of esophagitis and Barrett's length. Scandinavian Journal of Gastroenterology, 2012, 47, 900-906.	1.5	2
100	Experimental Intestinal Stenosis Alters Crohn's Disease-Like Intestinal Inflammation in Ileitis-Prone Mice. Digestive Diseases and Sciences, 2021, , 1.	2.3	1
101	Poor performance of predictive equations to estimate resting energy expenditure in patients with Crohn's disease. British Journal of Nutrition, 2023, 129, 272-282.	2.3	1
102	Editorial: an expert consensus to standardise the assessment of histologic disease activity in Crohn's disease clinical trialsâ€"a missing link. Alimentary Pharmacology and Therapeutics, 2021, 53, 749-750.	3.7	1
103	Histological diversity of anti-PD1-induced colitis Histology and Histopathology, 2022, , 18456.	0.7	1
104	O-036â€f Dysregulated Sphingosine-1-phosphate Pathway. Inflammatory Bowel Diseases, 2013, 19, S19.	1.9	0
105	At the Junction of Immunity and Barrier Function: The Immunomodulatory Protein TL1A May Also Regulate Intestinal Permeability. Digestive Diseases and Sciences, 2019, 64, 1728-1730.	2.3	0
106	Vitamin D Levels May Predict Response to Vedolizumab. Journal of Crohn's and Colitis, 2021, 15, 1978-1979.	1.3	0
107	Specific Neuropeptide Expression in Crohn's Disease Ileocolonic Resection Specimens Is Not Associated with Plexitis at the Ileal Margin or Postoperative Recurrence. Journal of Gastrointestinal Surgery, 2022, 26, 887-899.	1.7	0
108	Letter: <scp>COVID</scp> â€19 outcomes and <scp>antiâ€TNF</scp> treatmentsâ€"comprehensive evidence matters. Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 1235-1236.	3.7	0